Anthracyclines: biosynthesis, engineering and clinical applications

Natural Product Reports, vol. 39, pp. 814–841

Abstract

Anthracyclines are important anticancer drugs. We discuss recent insights into the biosynthetic pathways and bioactivities of anthracyclines, and evaluate the discovery and engineering of effective derivatives with less severe side effects.

Authors 5

1. Mandy B. Hulst Aachen Institute of Biology, Leiden University

   Leiden University

   Affiliation as printed

   Institute of Biology, Leiden University, Sylviusweg 72, 2333 BE Leiden, The Netherlands

2. Thadée Grocholski

   University of Turku

   Affiliation as printed

   Department of Life Technologies, University of Turku, FIN-20014 Turku, Finland

3. Jacques Neefjes Aachen Department of Cell and Chemical Biology and Oncode Institute

   Leiden University · Leiden University Medical Center

   Affiliation as printed

   Department of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Centre, Leiden, The Netherlands

4. Gilles P. van Wezel corresponding Aachen Institute of Biology, Leiden University

   Leiden University

   Affiliation as printed

   Institute of Biology, Leiden University, Sylviusweg 72, 2333 BE Leiden, The Netherlands

5. Mikko Metsä‐Ketelä corresponding

   University of Turku

   Affiliation as printed

   Department of Life Technologies, University of Turku, FIN-20014 Turku, Finland